Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes

The risk of long-term diabetes complications is not fully explained by diabetes duration or long-term glycemic exposure, suggesting the involvement of genetic factors. Because thiamine regulates intracellular glucose metabolism and corrects for multiple damaging effects of high glucose, we hypothesized that variants in specific thiamine transporters are associated with risk of severe retinopathy and/or severe nephropathy because they modify an individual’s ability to achieve sufficiently high intracellular thiamine levels. We tested 134 single nucleotide polymorphisms (SNPs) in two thiamine transporters (SLC19A2/3) and their transcription factors (SP1/2) for an association with severe retinopathy or nephropathy or their combination in the FinnDiane cohort. Subsequently, the results were examined for replication in the DCCT/EDIC and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) cohorts. We found two SNPs in strong linkage disequilibrium in the SLC19A3 locus associated with a reduced rate of severe retinopathy and the combined phenotype of severe retinopathy and end-stage renal disease. The association for the combined phenotype reached genome-wide significance in a meta-analysis that included the WESDR cohort. These findings suggest that genetic variations in SLC19A3 play an important role in the pathogenesis of severe diabetic retinopathy and nephropathy and may explain why some individuals with type 1 diabetes are less prone than others to develop microvascular complications.

[1]  Angelo J. Canty,et al.  The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy , 2014, Human Genetics.

[2]  Angelo J. Canty,et al.  The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy , 2014, Human Genetics.

[3]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[4]  J. Hirschhorn,et al.  Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. , 2013, Journal of the American Society of Nephrology : JASN.

[5]  Benjamin J. Keller,et al.  New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes , 2012, PLoS genetics.

[6]  R. Gans,et al.  Effect of Benfotiamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy , 2012, PloS one.

[7]  Christian Gieger,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[8]  Paul J Thornalley,et al.  Emerging role of thiamine therapy for prevention and treatment of early‐stage diabetic nephropathy , 2011, Diabetes, obesity & metabolism.

[9]  Shelley B. Bull,et al.  BR-squared: a practical solution to the winner’s curse in genome-wide scans , 2011, Human Genetics.

[10]  Henrik,et al.  Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index , 2012 .

[11]  Christian Gieger,et al.  Edinburgh Research Explorer Common variants at 10 genomic loci influence hemoglobin A(C) levels via glycemic and nonglycemic pathways , 2010 .

[12]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[13]  R. Gans,et al.  A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy , 2010, Diabetes Care.

[14]  Hitoshi Suzuki,et al.  Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy. , 2009, The New England journal of medicine.

[15]  T. Begley,et al.  The structural and biochemical foundations of thiamin biosynthesis. , 2009, Annual review of biochemistry.

[16]  John P. A. Ioannidis,et al.  Validating, augmenting and refining genome-wide association signals , 2009, Nature Reviews Genetics.

[17]  C. Forsblom,et al.  Heritability of Proliferative Diabetic Retinopathy , 2008, Diabetes.

[18]  M. Brownlee,et al.  Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes , 2008, Diabetologia.

[19]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[20]  R. Babaei-Jadidi,et al.  High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease , 2007, Diabetologia.

[21]  Felix Eichinger,et al.  Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.

[22]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[23]  Elena Berrone,et al.  Regulation of Intracellular Glucose and Polyol Pathway by Thiamine and Benfotiamine in Vascular Cells Cultured in High Glucose* , 2006, Journal of Biological Chemistry.

[24]  Merlin C. Thomas,et al.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.

[25]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[26]  H. Said,et al.  Characterization of the 5'-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[27]  J. Tuomilehto,et al.  Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. , 2004, Diabetes.

[28]  R. Babaei-Jadidi,et al.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. , 2003, Diabetes.

[29]  H. Hammes,et al.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.

[30]  Matthew D. Davis,et al.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. , 2002, JAMA.

[31]  I. Goldman,et al.  SLC19A3 encodes a second thiamine transporter ThTr2. , 2001, Biochimica et biophysica acta.

[32]  P. Martin,et al.  Molecular mechanisms of thiamine utilization. , 2001, Current molecular medicine.

[33]  B. Wlodarczyk,et al.  Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. , 2000, Molecular genetics and metabolism.

[34]  T. Nishikawa,et al.  The missing link: a single unifying mechanism for diabetic complications. , 2000, Kidney international. Supplement.

[35]  G. Gascon,et al.  Biotin-responsive basal ganglia disease: a novel entity. , 1998, Brain : a journal of neurology.

[36]  M. Porta,et al.  Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions , 1996, Diabetologia.

[37]  The Absence of a Glycemic Threshold for the Development of Long-Term Complications: The Perspective of the Diabetes Control and Complications Trial , 1996, Diabetes.

[38]  Barbara E K Klein,et al.  Epidemiology of Proliferative Diabetic Retinopathy , 1992, Diabetes Care.

[39]  J. Assal,et al.  [Long-term complications in diabetes mellitus]. , 1989, Acta medica portuguesa.

[40]  S. Lageman,et al.  National Institute of Neurological Disorders and Stroke , 2017 .

[41]  J. Hirschhorn,et al.  Chromosome 2 q 31 . 1 Associates with ESRD in Women with Type 1 Diabetes , 2013 .

[42]  Tanya M. Teslovich,et al.  Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index , 2010 .

[43]  Pak Chung Sham,et al.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..

[44]  G. Rindi,et al.  Thiamine intestinal transport and related issues: recent aspects. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[45]  The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. , 1996, Diabetes.